Skip to main content
SpringerLink
Log in

Immuntherapie maligner Non-Hodgkin-Lymphome

Immunotherapy of malignant non-Hodgkin’s lymphomas

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Auch wenn in den vergangenen Jahren z. T. eine Verbesserung der Prognose von Non-Hodgkin-Lymphomen (NHL) bereits mit veränderten konventionellen und eskalierten Chemotherapieverfahren indolenter und aggressiver Lymphome erreicht werden konnte, verläuft für einen großen Teil der Patienten die Tumorerkrankung noch immer fatal. Da eine weitere Optimierung konventioneller Modalitäten schwer möglich erschien, stellte die Etablierung immuntherapeutischer Ansätze eine attraktive Option dar. Die erfolgreiche Einführung monoklonaler Antikörper in die Behandlung maligner Lymphome hat die Immuntherapie fest etabliert. Weiterentwicklungen dieses passiven Immuntherapieansatzes sind auf dem Weg in den klinischen Alltag. Daneben sind unterschiedliche Verfahren aktiver Immunisierung (Vakzinierung) in präklinischen und frühen klinischen Entwicklungen, deren Etablierung eine weitere Bereicherung des therapeutischen Armentariums darstellen kann. Zuletzt hat — insbesondere für Hochrisikopatienten — die allogene Stammzelltransplantation in der jüngsten Vergangenheit an Attraktivität gewonnen.

Abstract

Even if improvements in conventional or dose-escalated chemotherapeutic approaches have positively influenced the results of treatment of indolent or aggressive non-Hodgkin’s lymphoma (NHL), most of the patients with malignant lymphoma ultimately die of their disease. In addition to traditional treatment tools, immunotherapeutic approaches now have been widely accepted as part of standard therapies of indolent and aggressive NHL. Mainly monoclonal antibodies for passive immunotherapy have become well established. However, studies investigating active immunization are under way using various approaches. Most recently, allogeneic transplantation has become more attractive, especially for high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bendandi M, Gocke CD, Kobrin CB et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 10:1171–1177

    Google Scholar 

  2. Coiffier B, Haioun C, Ketterer N et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: multicenter phase II study. Blood 92:1927–1932

    Google Scholar 

  3. Coiffier B, Feugier P, Sebban C et al. (2004) Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell-Lymphoma. Blood 103:1383a

    Google Scholar 

  4. Coiffier B, Lepage E, Briere J et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  5. Czuczman MS, Grillo-López AJ, White CA et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

    CAS  PubMed  Google Scholar 

  6. Czuczman MS, Weaver R, Alkuzweny B et al. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4659–4664

    Google Scholar 

  7. Davis TA, Maloney DG, Czerwinski DK et al. (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s Lymphoma without eradicating the malignant clone. Blood 92:1185–1190

    Google Scholar 

  8. Ehrlich P (1957) Über den jetzigen Stand der Karzinomforschung. In: The Collected Papers of Paul Ehrlich. Pergamon Press, London, UK, II, 550–557

  9. Lenz G, Dreyling M, Hoster E et al. (2005) Immunochemotherapy with Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology 23:1984–1992

    Google Scholar 

  10. Fisher RI, Dana BW, LeBlanc M et al. (2000) Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18:2010–2016

    Google Scholar 

  11. Hainsworth J, Litchy S, Grec FA et al. (2003) Scheduled Rituximab maintenance therapy versus Rituximab retreatment at progression in patients with indolent non-Hodgkin’s lymphoma (NHL) responding to single-agent Rituximab: a randomized trial of the Minnie Pearl Cancer Research Network. Blood 102:231a

    Google Scholar 

  12. Herold M, Pasold R, Srock S et al. (2004) Results of a prospective randomized open label phase III study comparing Rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma. Blood 104:584a

    Google Scholar 

  13. Ghielmini M, Schmitz SF, Cogliatti SB et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416–4423

    Article  CAS  PubMed  Google Scholar 

  14. Hiddemann W, Dreyling MH, Forspointer R et al. (2003) Combined immunochemotherpy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102:352a

    Google Scholar 

  15. Hsu FJ, Caspar C, Czerwinski D et al. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long term results of a clinical trial. Blood 89:3129–3135

    Google Scholar 

  16. Kaminiski MS, Tuck M, Estes J et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449

    Google Scholar 

  17. Kimby E (2002) Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. Semin Oncol 29 [2 Suppl 6]

    Google Scholar 

  18. Maloney DG, Liles TM, Czerwinski DK et al. (1994) Phase I clinical trial using escalating single-dose infusions of chimeric anti-CD20 antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma: Blood 84:2457–2466

    Google Scholar 

  19. Maloney DG, Grillo-López AJ, White CA et al. (1998) IDEC-C2B8 (Rituximab) anti-CD20 antibody therapy of patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195

    Google Scholar 

  20. Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423

    Google Scholar 

  21. McLaughlin P, Grillo-López AJ, Link BK et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    CAS  PubMed  Google Scholar 

  22. Miller RA, Maloney DG, Warnke R et al. (1982) Treatment of B-cell lymphoma with monoclonal anti-idotype antibody. N Engl J Med 306:517–522

    Google Scholar 

  23. Morschhauser F, Huglo D, Martinelle G et al. (2004) Yttrium-90 Ibritumomab Tiuxetan for patients with relapsed/refractory diffuse large cell B-Cell Lymphoma not appropriate for autologous stem cell transplantation: Results of an Open-Label Phase II Trial. Blood 104:130a

    Google Scholar 

  24. Morris E, Thomson K, Craddock C et al. (2004) Outcomes after alemtuzumab-containing reduced intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin Lymphoma. Blood 104:3865–3871

    Google Scholar 

  25. Nadler LM, Stashenko P, Hard R et al. (1980) Serotherapy of patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154

    Google Scholar 

  26. Osterborg A, Dyer MJS, Bunjes D et al. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567–1573

    Google Scholar 

  27. Pfreundschuh M, Truemper L, Devinder G et al. (2004) First analysis of the completed Mabthera international (MINT) trial in young patients with low-risk diffuse large-B-cell lymphoma: addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 104: 157a

    Google Scholar 

  28. Press OW, Appelbaum F, Ledbetter JA et al. (1981) Monoclonal antibody 1F5 (anti-CD-20) serotherapy of human B-cell lymphomas. Blood 69:584–591

    Google Scholar 

  29. Press OW, Eary JF, Gooley T et al. (2000) A phase I/II trial of iodine 131 tositumomab (anti-CD20), etoposide, cyclophoshamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934–2942

    Google Scholar 

  30. Rohatiner A, Radford J, Deakin D et al. (2001) A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 85:29–35

    Google Scholar 

  31. Rohatiner AZ, Gregory WM, Peterson B et al. (2002) A metaanalysis of randomised studies evaluation of the role of interferon alpha as treatment for follicular lymphoma. Proc ASCO 21:1053a

    Google Scholar 

  32. Stevenson FK, Ottensmeier CH, Johnson P et al. (2004) DNA Vaccines to attack cancer. PNAS 101:14646–14652

    Google Scholar 

  33. Timmerman JM, Czerwinski DK, Davis TA et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526

    Article  CAS  PubMed  Google Scholar 

  34. van Besien K, Loberiza FR, Bajorunaite R et al. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521–3529

    Google Scholar 

  35. Vose JM, Wahl RL, Saleh M et al. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18:1316–1323

    Google Scholar 

  36. Weidmann E, Hess G, Krause SW et al. (2004) Combination chemoimmunotherapy using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas. Blood 104:2640a

    Google Scholar 

  37. Witzig TE, White CA, Wiseman GA et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17:3793–3803

    CAS  PubMed  Google Scholar 

  38. Witzig TE, Gordon LI, Cabanillas F et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463

    Article  CAS  PubMed  Google Scholar 

  39. Witzig TE, Flinn IW, Gordon LI et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262–3269

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz

    G. Heß

  2. III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Langenbeckstraße 1, 55101, Mainz

    G. Heß

Authors
  1. G. Heß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Heß.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heß, G. Immuntherapie maligner Non-Hodgkin-Lymphome. Onkologe 11, 571–577 (2005). https://doi.org/10.1007/s00761-005-0869-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-005-0869-6

Schlüsselwörter

Keywords

Search

Navigation